

# Margaret K. Kyle

Toulouse School of Economics  
Manufacture des Tabacs - MF 406  
21, allée de Brienne  
31000 Toulouse  
France  
Citizenship: United States

Office: +33 (0)5 61 12 86 32  
Email: [margaret.kyle@tse-fr.eu](mailto:margaret.kyle@tse-fr.eu)  
Homepage: [www.margaretkyle.net](http://www.margaretkyle.net)

## Education

B.S. with honors, Cornell University, 1992-1995.

Ph.D. Economics, Massachusetts Institute of Technology, 1997-2002.

## Teaching and Research Fields

Industrial Organization, Productivity, Economics of Innovation, Health Policy

## Work Experience

Professeur, Université de Toulouse 1 (Institut d'Administration des Entreprises) and Toulouse School of Economics, 2010-.

Professeur associé, Université de Toulouse 1, 2009-2010.

Assistant Professor, London Business School, 2006-2010 (on leave 2009-10).

Assistant Professor, Duke University, Fuqua School of Business, 2004-2006.

Assistant Professor, Carnegie Mellon University, Tepper School of Business, 2002-2004.

Visiting Scholar, Center for the Study of Innovation and Productivity, Federal Reserve Bank of San Francisco, 2003.

Research Assistant, Board of Governors of the Federal Reserve System, 1995-1997.

## Research

### *Publications in refereed journals*

“Deregulating Direct-to-consumer Marketing of Prescription Drugs: Effects on Prescription and Over-the-counter Sales,” with Ernst R. Berndt and Davina Ling (2002), *Journal of Law and Economics* 44 (3), 691-723.

“Measuring health impacts on work performance: Comparing subjective and objective reports,” with Glenn Pransky, Ernst Berndt, Stan Finkelstein, Joan Mackell, and Dan Tortorice (2002), *Value in Health* 5(6), 448-449.

“Public & Private Spillovers, Location, and the Productivity of Pharmaceutical Research,” with Jeff Furman, Iain Cockburn, and Rebecca Henderson, *Annales d'Economie et Statistique* 2005, 79/80, 165-188.

“Surviving the Gales of Creative Destruction: The Determinants of Product Turnover,” with John M. de Figueiredo (2006), *Strategic Management Journal* 27(3), 241-264.

“Objective and Self-Reported Work Performance Measures: A Comparative Analysis,” with Glenn Pransky, Ernst Berndt, Stan Finkelstein, Joan Mackell, and Dan Tortorice (2006), *International Journal of Productivity & Performance Management* 55(5), 390-399.

“The Role of Firm Characteristics in Pharmaceutical Product Launches,” *RAND Journal of Economics* Autumn 2006, 37(3), 602-618.

“Pharmaceutical Price Controls and Entry Strategies,” *Review of Economics and Statistics* February 2007, 89(1), 88-99

“Generic Competition and Market Exclusivity Periods in Pharmaceuticals,” with Henry Grabowski, *Managerial and Decision Economics* June-August 2007, 28(4-5), 491-502.

“Would Greater Price Transparency and Uniformity Benefit Poor Patients?” with David Ridley, *Health Affairs* Sept/Oct 2007, 26(5), 1384-1391.

“Does Re-importation Reduce Price Differences for Prescription Drugs? Lessons from the European Union,” with Jennifer Allsbrook and Kevin Schulman, *Health Services Research* August 2008, 43(4), 1308-1324.

“Intervening in global markets to improve access to HIV/AIDS treatment: an analysis of international policies and the dynamics of global antiretroviral medicines markets” (with Brenda Waning, Ellen Diedrichsen, Lyne Soucy, Jenny Hochstadt, Till Barnighausen and Suerie Moon), *Globalization and Health* 2010, 6:9.

“Strategic Responses to Parallel Trade” (2011), *The B.E. Journal of Economic Analysis & Policy*: Vol. 11 : Iss. 2 (Advances), Article 2.

“Investments in Pharmaceuticals Before and After TRIPS,” with Anita McGahan, March 2011 (previous version: NBER Working Paper 15468), forthcoming in *Review of Economics and Statistics*.

“Assessing the population health impact of market interventions to improve access to antiretroviral treatment,” with Till Barnighausen, Joshua Salomon and Brenda Waning, September 2011, forthcoming in *Health Policy and Planning*.

“Evolution of Market Exclusivity, Paragraph IV Challenges and Generic Penetration,” with Henry Grabowski, Richard Mortimer, Genia Long and Noam Kirson, September 2011, forthcoming in *Health Affairs*.

### *Book chapters and other publications*

“Did U.S. Bank Supervisors Get Tougher During the Credit Crunch? Did it Matter to Bank Lending?” with Allen N. Berger and Joseph M. Scalise in *Prudential Supervision: What Works and What Doesn't*, edited by Frederic Mishkin (Chicago: University of Chicago Press, 2001).

“The Long Shadow of Patent Expiration: Do Rx to OTC Switches Provide an Afterlife?” with Ernst R. Berndt and Davina Ling, in *NBER Conference Volume on Scanner Data and Price Indexes*, edited by Robert Feenstra and Matthew Shapiro (Chicago: University of Chicago Press, 2003), 229-267.

“Does Locale Affect R&D Activity? The Case of Pharmaceuticals,” *Federal Reserve Bank of San Francisco Economic Letter*, Nov. 13, 2004.

“Product Launch Decisions by Dominant and Fringe Firms,” with John M. de Figueiredo, *Best Paper Proceedings of the Academy of Management*, 2005.

“Mergers and Alliances in Pharmaceuticals: Effects on Innovation and R&D Productivity,” with Henry Grabowski, in *The Economics of Corporate Governance and Mergers*, edited by Klaus Peter Gugler and B. Burcin Yurtoglu (Cheltenham, UK: Edward Elgar Publishing, 2008).

“Innovation in the Pharmaceutical Industry,” report prepared for the National Endowment for Science, Technology and the Arts, May 2008.

“Comparative advantages of push and pull incentives for technology development: lessons for neglected diseases” with Cheri Grace, in *Global Forum Update on Research for Health Volume 6*, 2009.

“Parallel Trade in Pharmaceuticals: Firm Responses and Competition Policy,” Chapter 13 in *International Antitrust Law & Policy: Fordham Competition Law 2009*, edited by Barry Hawk (Juris Publishing, New York, 2009).

“Consolidation and Productivity in the Pharmaceutical Industry,” with Henry Grabowski, November 2010, forthcoming in *Handbook of the Economics of the BioPharmaceutical Industry*.

“The Market for Pharmaceuticals,” with Fiona Scott Morton, July 2011, forthcoming in *Handbook of Health Economics*.

### *Papers Under Review*

“Inefficiencies in the Sale of Ideas: Theory and Empirics,” with Marie-Laure Allain and Emeric Henry, September 2011.

“The Influence of Intellectual Property Rights on the Geography of Trade in Knowledge-Intensive Goods,” with Mercedes Delgado and Anita McGahan, May 2011 (revise and resubmit, *Journal of Industrial Economics*).

### *Work in Progress*

“The Impact of Funding for Neglected Diseases,” with David Ridley

“Parallel Trade and Price Controls,” with Patrick Rey

“The Market for Antiretrovirals in Developing Countries” with Brenda Waning

“Strategic Disclosure of Research Results in Clinical Trials,” with Emeric Henry

“Corporate IP Donations to Universities: Are Donated Patents Lemons or Orphans?”

## **Invited Talks**

2001-2002: Boston University School of Management, UC-Irvine Graduate School of Management, Carnegie Mellon University GSIA, Washington University in St. Louis, Olin School of Business, University of Michigan, Ford School of Public Policy, U.S. Department of Justice, UC-Davis Department of Economics, Federal Reserve Bank of San Francisco, Board of Governors of the Federal Reserve System, University of Toronto Rotman School of Management, London Business School, University of Washington, School of Business, NBER Productivity Lunch, NBER Summer Institute.

2002-2003: Duke University Fuqua School of Business, Stanford Strategic Management Conference, International Health Economics Conference, NBER-CREST Joint Conference on R&D, Education, and Productivity.

2003-2004: Federal Reserve Bank of San Francisco, Wharton Technology Conference, Northwestern University Kellogg Graduate School of Management, International Schumpeter Society Conference, Southern Economics Association Conference, International Health Economics Association Conference.

2004-2005: NBER Productivity Lunch, Duke University Department of Economics, University of Miami, Cornell University.

2005-2006: Lehigh University, University of Toulouse, London Business School, HEC Lausanne, London School of Economics, Imperial College, New York University, NBER Summer Institute.

2006-2007: OECD Committee for Science and Technological Policy meeting, DRUID Winter Conference, Strategy Research Forum, International Health Economics Association Conference, NBER Pre-conference on Location of Biopharmaceutical Activity.

2007-2008: University of Basel, University of St. Andrews, Paris School of Economics, NBER Productivity Lunch, NBER Conference on the Location of Biopharmaceutical Activity, Duke Strategy Conference, MIT Business and Public Policy Conference, American Society of Health Economists Conference, Knowledge for Growth Conference, NBER Summer Institute.

2008-2009: Markets for Technology Conference, London Business School, Wharton, University of Missouri, Harvard Business School, INSEAD, Emory University, NBER Productivity Lunch, Duke University Fuqua School, HEC Lausanne, Free University of Brussels, University of Toulouse, Imperial College, Network of Industrial Economists Conference.

2009-2010: Fordham Conference on International Antitrust Law and Policy, European School of Management and Technology, Wharton Conference on the Pharmaceutical Industry, University of Tokyo, University of Zurich, Korea-US Healthcare Innovation Seminar.

2010-2011: Toulouse School of Economics (IO and IP workshops), Pharmaceutical Economics and Policy Council conference, University of Basel, CSIO-IDEI conference.

2011-2012 (planned): EARIE conference, University of Zurich, Triangle Health Economics seminar.

## Teaching

### *Toulouse School of Economics/University of Toulouse 1*

Business Economics (M2)

Advanced Strategy (M1)

Thinking Strategically (M1)

### *University of Basel, Zaeslin Program in Law and Economics*

Competition and Regulation in the Pharmaceutical Industry, 2009-.

*London Business School*

Economics of Competitive Strategy (MBA elective), Fall 2006, Spring 2008.

Strategy in Innovative Industries (MBA elective), Fall 2008.

Core Strategy (EMBA programs), Spring and Summer 2007, Spring 2008.

*Duke University, Fuqua School of Business*

Core Strategy (EMBA programs), Fall 2004, Fall 2005, Spring 2006.

Management of Innovation and Technology (MBA elective), Fall 2005, Spring 2005.

*Carnegie Mellon University, Tepper School of Business*

Technology Strategy (MBA elective). Spring 2003 (2 sections), Spring 2004 (4 sections)

Technology Strategy (undergraduate elective). Spring 2003

Economics of Innovation (PhD course). Spring 2004

**Professional Activities***Refereeing*

*American Economic Review, Journal of Political Economy, Review of Economic Studies, Review of Economics and Statistics, RAND Journal of Economics, Journal of Industrial Economics, Journal of Development Economics, Journal of Law and Economics, Journal of Economic Analysis and Policy, Economic Inquiry, Economic Journal, Health Economics, Journal of Health Economics, Health Affairs, Economics of Innovation and New Technology, Economic Inquiry, Southern Economic Journal, Journal of Regulatory Economics, Journal of Applied Econometrics, Journal of Economic and Business Statistics, Journal of Banking and Finance, Journal of Money, Credit and Banking, International Journal of Health Care Finance and Economics, Review of Industrial Organization, Social Science and Medicine, Management Science, Strategic Management Journal, Research Policy, Academy of Management Journal, National Science Foundation, UK Economic and Social Research Council, Netherlands Organisation for Scientific Research.*

*Professional Memberships*

Faculty Research Fellow, National Bureau of Economic Research, 2004-2010.

Research Associate (Industrial Organization), Centre for Economic Policy Research

American Economic Association